GlaxoSmithKline (NYSE:GSK) and Innoviva (NASDAQ:INVA) announce
the filing of a supplemental new drug application to the FDA for an
additional indication for the use of Trelegy Ellipta for asthma in
adults.
The companies note Trelegy Ellipta was approved in
the U.S. in 2017 for the treatment of patients with chronic obstructive
pulmonary disease.
Source: Press Release
https://seekingalpha.com/news/3503328-glaxosmithkline-innoviva-look-new-trelegy-use
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.